Triplet therapy for prostate cancer
Mené en Europe entre 2013 et 2018 sur 1 173 patients atteints d'un adénocarcinome de la prostate de novo, métastatique et sensible à la castration, cet essai randomisé multicentrique de phase III évalue l'efficacité, du point de vue de la survie sans progression radiographique et de la survie globale, et la toxicité d'un traitement associant abiratérone, prednisone (avec ou sans radiothérapie) et thérapie anti-androgénique standard
The past 8 years have seen four agents shown to be superior to androgen deprivation therapy (ADT) alone in terms of overall survival when given as doublet therapy with ADT for metastatic castration-sensitive prostate cancer. In The Lancet, Karim Fizazi and colleagues report the findings from the PEACE-1 trial, which provides evidence in support of triplet therapy for metastatic castration-sensitive prostate cancer. The trial enrolled 1173 male patients (aged ≥18 years, across Belgium, France, Ireland, Italy, Romania, Spain, and Switzerland) with synchronous (de novo) metastatic hormone-sensitive prostate cancer who received ADT (plus docetaxel in 60% of patients) as standard of care alone, or standard of care with the addition of abiraterone plus prednisone (hereafter referred to as abiraterone), radiotherapy to the primary tumour, or abiraterone plus radiotherapy, in a randomised 2 × 2 factorial design.
The Lancet , commentaire en libre accès, 2021